Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E4MT | ISIN: US78397T2024 | Ticker-Symbol:
NASDAQ
04.06.25 | 15:31
1,860 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SAB BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SAB BIOTHERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur SAB BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.05.SAB Biotherapeutics reports Q1 results2
09.05.SAB Biotherapeutics, Inc.: SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates220MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human...
► Artikel lesen
09.05.SAB Biotherapeutics, Inc. - 10-Q, Quarterly Report1
03.04.SAB Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans3
SAB BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
01.04.SAB Biotherapeutics stock holds $6 target with Buy rating2
31.03.SAB Biotherapeutics reports FY results3
31.03.SAB Biotherapeutics, Inc.: SAB BIO Reports Full Year 2024 Operating and Financial Results264MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human...
► Artikel lesen
05.02.SAB Biotherapeutics, Inc. - 8-K, Current Report-
28.01.Why Is SAB BIO Stock Trading Lower On Tuesday?6
28.01.Pre-market Movers: IMAC Holdings, Planet Image International, SAB Biotherapeutics, MicroCloud Hologram, Avalon Holdings723BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green IMAC Holdings, Inc. (BACK) is up over 91% at $1.59. Planet...
► Artikel lesen
28.01.SAB Biotherapeutics, Inc.: SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142411SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support...
► Artikel lesen
28.01.SAB Biotherapeutics, Inc. - 8-K, Current Report-
23.01.SAB Biotherapeutics, Inc.: SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy4
06.01.Here's Why SAB Biotherapeutics, Inc. (NASDAQ:SABS) Is Among the Best Diabetes Stocks to Buy Under $101
06.11.24SAB Biotherapeutics, Inc.: SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update195Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year. MIAMI, Nov....
► Artikel lesen
08.08.24SAB Biotherapeutics, Inc.: SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates259FDA provided clearance to SAB's IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS)...
► Artikel lesen
05.08.24SAB Biotherapeutics, Inc.: SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes597MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing...
► Artikel lesen
31.07.24SAB Biotherapeutics, Inc.: SAB BIO Appoints Lucy To as Chief Financial Officer186MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is...
► Artikel lesen
20.06.24SAB Biotherapeutics, Inc.: SAb Biotherapeutics Rebrands as SAB BIO256New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE)...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1